Ionis Pharmaceuticals
NasdaqGS:IONS Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
AN
Consensus Narrative from 24 Analysts
Anticipated Drug Launches Will Shift Biotech Company To Commercial Stage
Key Takeaways Ionis is set to boost revenue through first-mover advantage with TRYNGOLZA and other product launches targeting unmet medical needs. Significant growth is expected from partner and independent product launches, enhancing diversification and potentially leading to positive cash flow.
View narrativeUS$59.50
FV
45.8% undervalued intrinsic discount19.75%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
5 days ago author updated this narrative